Belite Bio Inc ADR (BLTE)
NASDAQ: BLTEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 3:48 PM ET
BLTE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.16B
- Forward P/E
- 67.66
- EPS (TTM)
- -$2.74
- Dividend yield
- None
- 52-week range
- 77.13 – 200.00
- Day range
- 150.21 – 155.85
- Volume / Avg
- 135.87K / 178.90K
- Beta
- —
- Shares outstanding
- 40.27M
52-week range
BLTE stock today
Shares of Belite Bio (BLTE) are trading lower on Oct 8 at $152.91, a drop of 2.03% or $3.17 per share, versus the S&P 500's 0.49% decline. Shares are 23.5% below their 52-week high of $200.00, set on Feb 3, 2026 and 98.3% above the 52-week low of $77.13, in the middle of the past year's range. BLTE is down 2.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 101.7%.
Belite Bio has posted a net loss over the last twelve months (EPS of -$2.74), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Belite Bio
Company profileBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Yu-Hsin Lin M.B.A., Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 41
- IPO year
- 2022
- Website
- belitebio.com
Financial highlights
Full financialsBelite Bio reported a net loss of $77.6 million, compared with a loss of $36.1 million a year earlier. Diluted earnings per share came in at -$2.31.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-77.61M | $-36.14M | $-31.63M | $-12.65M | $-9.67M |
| EPS (diluted) | $-2.31 | $-1.18 | $-1.19 | $-0.63 | $-1.01 |
Analyst forecast
ForecastConsensus (9 analysts)
none
Avg. price target
$228.89+49.69%
- Strong buy 2
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Belite Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RYTMRhythm Pharmaceuticals Inc. | 89.22 | +0.87% | $6.14B | vs BLTE |
| KNSAKiniksa Pharmaceuticals International plc Class A | 78.56 | +0.76% | $6.13B | vs BLTE |
| LGNDLigand Pharmaceuticals Incorporated | 294.01 | +0.25% | $5.86B | vs BLTE |
| ALKSAlkermes plc | 40.11 | -3.22% | $6.73B | vs BLTE |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.57 | -0.43% | $6.81B | vs BLTE |
| ERASErasca Inc. | 15.53 | +9.99% | $5.43B | vs BLTE |
| IONSIonis Pharmaceuticals Inc. | 43.31 | -1.92% | $7.20B | vs BLTE |
| MIRMMirum Pharmaceuticals Inc. | 81.40 | +0.95% | $5.29B | vs BLTE |
Indexes, lists and sector
Belite Bio stock FAQ
What is Belite Bio's stock price today?
BLTE last traded at $152.91 as of Oct 8, 3:48 PM EDT, down 2.03% on the day. Prices are delayed at least 15 minutes.
Who is Belite Bio's CEO?
Dr. Yu-Hsin Lin M.B.A., Ph.D. is the chief executive officer of Belite Bio Inc ADR, which has about 41 employees.
What is the BLTE 52-week high?
The 52-week high for BLTE is $200.00 and the 52-week low is $77.13. The stock is currently 23.5% below its high.